You are here

Vascular & Endovascular

 - globe

Man or woman, prescription rates for stroke-preventing anticoagulants were no different for patients with nonvalvular atrial fibrillation (AF) in a global study. However, on the whole the same anticoagulation rates showed inadequate thromboprophylaxis in the majority of patients.

 - endovascular, peripheral vascular disease

The Centers for Medicare & Medicaid Services (CMS) has approved supplemental reimbursement for two drug-coated balloons to treat Medicare patients with peripheral artery disease, but the payment applies only to outpatient settings.

 - brain, stroke

Even a minor stroke can lead to disability if paired with an intracranial occlusion. Researchers explored the use of tenecteplase (TNK) tissue-type plasminogen activator (tPA) to safely treat this type of stroke before it progressed.

 - Drip

Could something as simple as water create a sea change in stroke care? A study unveiled Feb. 12 pointed to dehydration as a factor in poor stroke outcomes, making rehydration a possible pathway for improvement, the lead researcher told Cardiovascular Business

 - bleeding_stroke

Providing more proof that time is brain, a randomized trial found that promptly performing thrombectomy with a stent retriever in carefully selected ischemic stroke patients led to better outcomes than did alteplase treatment alone.

 

More Stories

Amputations in PAD patients drop 45% over 15 years

The rate of lower limb amputations in Medicare patients with peripheral artery disease (PAD) took a nosedive over the past 15 years while endovascular interventions rose, according to a study published in the January issue of JAMA Surgery.

Time to recalibrate? Stroke risk may be lower than reported

Stroke risks after an atrial fibrillation diagnosis may be lower than previously thought. The finding, published Jan. 27 in the Journal of the American College of Cardiology, has prompted a call to reassess oral anticoagulation among these patients.

Real-world CAS outcomes not as rosy as controlled trials

Carotid artery stenting (CAS) may benefit patients by reducing stroke risks in the long term, but recent data suggest that they may not be living long enough for that benefit to bear fruit. According to a study published online Jan. 12 in JAMA Neurology, 32 percent of elderly CAS patients died within two years of the procedure.

Anticoagulant reversal works in preliminary study

In close timing with the FDA’s approval of edoxaban for reducing the risk of stroke in patients with atrial fibrillation, researchers reported that an agent reversed edoxaban’s anticoagulant effect in a phase 1 study.

FDA approves edoxaban for reducing stroke risk

The FDA followed the advice of its advisory panel and added another novel oral anticoagulant to its approved drug list.

Feds sue cardiologist who topped Medicare’s fee list

The Department of Justice (DoJ) is taking the reins in two lawsuits filed against a Florida cardiologist who made headlines in 2014 for billing Medicare $18 million in one year. The DoJ alleges he performed medically unnecessary interventions and paid kickbacks to patients.

FDA OKs IN.PACT drug-coated balloon for PAD patients

The FDA approved Medtronic’s drug-coated balloon as a treatment for peripheral artery disease (PAD), giving physicians more options for treating patients with disease in the superficial femoral artery and the popliteal artery.

Evidence supports BP monitoring on the go for at-risk patients

A meta-analysis of blood pressure monitoring studies supports closely monitoring patients at risk for hypertension and cardiovascular disease. This included support for using ambulatory methods on patients in order to prevent overdiagnosis due to office-related elevated blood pressure.

Age-adjusted test aims to reduce unneeded pulmonary embolism imaging

Hoping to reduce the frequency of unnecessary imaging in older patients, research published in the December issue of CHEST explored a sliding adjustment scale to D-dimer testing for pulmonary embolism.

Stroke care imperiled by impending shortage of vascular neurologists

A talent void is pending among stroke specialists, according to a study published in the December issue of Stroke. The question posed by the authors is how to increase the number of young vascular neurologists entering the pipeline to compensate for losses.

Intra-arterial therapy shines in MR CLEAN stroke trial

Giving patients with certain acute ischemic strokes intra-arterial treatment in addition to tissue plasminogen activator led to better outcomes compared with usual care, MR CLEAN researchers reported online Dec. 17 in the New England Journal of Medicine.

HDL cholesterol’s carrying capacity lowers risk for atherosclerosis

The removing ability of high-density lipoprotein (HDL) cholesterol may be the secret behind apparently “good” cholesterol, according to a study published Dec. 18 in the New England Journal of Medicine.

Circling back to ORBIT-AF: Bridging anticoagulation may increase bleeding, adverse events risk

Before you cross that bridge, consider: A fresh look at the data from ORBIT-AF suggests that bridging oral anticoagulation instead of temporary cessation for a procedure may put patients at greater risk for bleeding or adverse events.

Deep dive into HTN-3 helps ID ways to improve

What, if anything, went wrong in the SYMPLICITY HTN-3 trial will probably remain up for debate, but a post hoc analysis may help to keep subsequent trials on the right path.

Risk of VTE increases with duration of surgery

Consider it one more reason to make that surgery a quick one. Researchers found that the longer a surgery goes, the more risk of venous thromboembolism (VTE) for the patient. 

ZOLL snaps up Philips’ InnerCool assets

ZOLL Medical is buying the assets from Philips’ InnerCool temperature management business, which includes several products cleared for use in the U.S.

Low-dose aspirin fails to impress in Japanese study

A subgroup analysis eventually may offer answers in a trial that assessed once-daily, low-dose aspirin to prevent atherosclerotic cardiovascular disease in Japan, according to a study published online Nov. 17 in JAMA. The trial was terminated early due to futility.

VIVA.14: Promising 1-year results for drug-coated balloons in diabetics

Patients with peripheral artery disease (PAD) and diabetes who underwent treatment with a drug-coated balloon fared better than counterparts who received standard care, according to a subanalysis of the IN.PACT SFA trial.

VIVA.14: Zilver PTX holds strong at five years

At five years, the Zilver PTX stent proved to be a durable treatment for peripheral artery disease with sustained benefit, results presented Nov. 4 at the 2014 Vascular Interventional Advances (VIVA) meeting showed.

VIVA.14: DISRUPT PAD brings lithoplasty technique to peripheral lesions

Shockwaves appear to have early success in breaking up calcified lesions safely. In research presented Nov. 5 at the 2014 Vascular Interventional Advances (VIVA) meeting in Las Vegas, a lithotripsy-with-balloon technique used on peripheral artery lesions resulted in all patients achieving less than 50 percent stenosis.